Company Xencor, Inc.

Equities

XNCR

US98401F1057

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Xencor, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 02:00:01 07/05/2024 am IST			5-day change	1st Jan Change
24.31 ^USD	+0.83%		+15.38%	+14.51%

16/04	BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating	MT
09/04	Xencor Names Bart Cornelissen as Chief Financial Officer	MT

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Number of employees: 280

USD in Million	2022	Weight	2023	Weight	Delta
Monoclonal Bispecific Antibody and Cytokine Therapeutics 100.0 %	165	100.0 %	168	100.0 %	+2.28%

USD in Million	2022	Weight	2023	Weight	Delta
Global 100.0 %	165	100.0 %	168	100.0 %	+2.28%

Managers	Title	Age	Since
Bassil Dahiyat FOU	Founder	53	01/97/01
John Desjarlais CTO	Chief Tech/Sci/R&D Officer	59	01/01/01
Charles Liles IRC	Investor Relations Contact	-	-
Jennifer Sandoz HRO	Human Resources Officer	-	-
Celia Eckert LAW	General Counsel	52	10/19/10
Jeremy Grunstein PRN	Corporate Officer/Principal	-	23/19/23
David Szymkowski PRN	Corporate Officer/Principal	60	01/02/01
Raphael Clynes PRN	Corporate Officer/Principal	-	08/17/08
Nancy Valente PRN	Corporate Officer/Principal	66	08/22/08
Dane Leone PRN	Corporate Officer/Principal	-	02/01

Members of the board	Title	Age	Since
Kevin Gorman BRD	Director/Board Member	66	14/17/14
Richard J. Ranieri BRD	Director/Board Member	71	19/17/19
Alan Bruce Montgomery BRD	Director/Board Member	70	18/15/18
Bassil Dahiyat FOU	Founder	53	01/97/01
Kurt Gustafson BRD	Director/Board Member	56	25/14/25
Ellen Feigal		69	-
Barbara Klencke BRD	Director/Board Member	66	15/23/15
Dagmar Rosa-Bjorkeson BRD	Director/Board Member	60	18/19/18
Nancy Valente PRN	Corporate Officer/Principal	66	08/22/08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	61,647,493	61,064,703 ( 99.05 %)	0	99.05 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 17.83 %	10,897,006	17.83 %	241 M $
PRIMECAP Management Co. 14.56 %	8,901,607	14.56 %	197 M $
Vanguard Fiduciary Trust Co. 11.07 %	6,767,249	11.07 %	150 M $
EcoR1 Capital, LLC 8.643 %	5,282,516	8.643 %	117 M $
T. Rowe Price International Ltd. 5.700 %	3,483,775	5.700 %	77 M $
STATE STREET CORPORATION 5.443 %	3,326,856	5.443 %	74 M $
Fidelity Management & Research Co. LLC 4.193 %	2,562,905	4.193 %	57 M $
Armistice Capital LLC 2.454 %	1,500,000	2.454 %	33 M $
T. Rowe Price Investment Management, Inc. 2.211 %	1,351,367	2.211 %	30 M $
Geode Capital Management LLC 2.151 %	1,314,943	2.151 %	29 M $

Name	Equities	%	Valuation
INMUNE BIO, INC. 10.46%	1,885,533	10.46%	22,155,013 $

Xencor, Inc.

465 North Halstead Street Suite 200

91016, Pasadena

+626 305 5900

http://www.xencor.com

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.31 USD

Average target price

36.18 USD

Spread / Average Target

+48.84%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
XENCOR, INC.	+14.51%	1.5B
REGENERON PHARMACEUTICALS, INC.	+9.15%	106B
VERTEX PHARMACEUTICALS INCORPORATED	-1.08%	104B
ARGENX SE	+6.90%	23.25B
BIONTECH SE	-11.55%	22.5B
GENMAB A/S	-6.91%	18.7B
WUXI APPTEC CO., LTD.	-37.08%	17.95B
BEIGENE, LTD.	-9.91%	16.99B
NEUROCRINE BIOSCIENCES, INC.	+7.55%	14.26B
SAREPTA THERAPEUTICS, INC.	+40.04%	12.76B

Bio Therapeutic Drugs